Evidence map›Paper›PMID 23616796›Full record

ArticleBeilstein journal of organic chemistry2013

Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes.

Tony Taldone, Anna Rodina, Erica M DaGama Gomes, Matthew Riolo, Hardik J Patel, Raul Alonso-Sabadell, Danuta Zatorska, Maulik R Patel, Sarah Kishinevsky, Gabriela Chiosis

Abstract read
In one paragraph

Article in Beilstein journal of organic chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.Cold Spring Harbor perspectives in biology · 2020
    Review
  6. Chaperome Networks - Redundancy and Implications for Cancer Treatment.Advances in experimental medicine and biology · 2020
    Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tony Taldone *Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Anna Rodina *Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Erica M DaGama GomesMolecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Matthew RioloMolecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Hardik J PatelMolecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Raul Alonso-SabadellMolecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Danuta ZatorskaMolecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Maulik R PatelMolecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Sarah KishinevskyMolecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Gabriela ChiosisMolecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Small molecule Hsp90 inhibitors in AD treatmentU01AG032969 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2010 to 2014
$3.5M
Biomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9M
Targeting the heat shock response for the therapy of DLBCLR01CA155226 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIOSIS, GABRIELA, MELNICK, ARI M. · 2011 to 2015
$2.5M
Design, synthesis and evaluation of selective Grp94 inhibitorsR21AI090501 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2010 to 2011
$460k
Biomarkers of response to Hsp90 inhibitors in triple-negative breast cancerR21CA158609 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2012 to 2013
$426k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA155226NCI NIH HHS R01 CA172546NCI NIH HHS R21 CA158609NIAID NIH HHS R21 AI090501NIA NIH HHS U01 AG032969
6 · The paper itself

Abstract

The attachment of biotin to a small molecule provides a powerful tool in biology. Here, we present a systematic approach to identify biotinylated analogues of the Hsp90 inhibitor PU-H71 that are capable of permeating cell membranes so as to enable the investigation of Hsp90 complexes in live cells. The identified derivative 2g can isolate Hsp90 through affinity purification and, as we show, represents a unique and useful tool to probe tumor Hsp90 biology in live cells by affinity capture, flow cytometry and confocal microscopy. To our knowledge, 2g is the only reported biotinylated Hsp90 probe to have such combined characteristics.

Indexed as

affinity capturebiotinflow cytometryfluorescence microscopyPU-H71tumor Hsp90

Identifiers

PMID23616796
PMCPMC3628991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.